Corgenix Medical Corp. (CONX: OTCQB) | Corgenix Announces New Grants to Advance Work on Ebola Test Kit

Corgenix Announces New Grants to Advance Work on Ebola Test Kit

Dec 24, 2014

OTC Disclosure News Service

Corgenix
Medical Corporation
(OTCQB: CONX.OB), a worldwide developer and
marketer of diagnostic test kits, has been awarded two grants totaling
$818,000 to advance the development of an Ebola rapid diagnostic test
kit.

The grants were awarded to Corgenix by the Bill
Melinda Gates Foundation
and the Paul
G. Allen Family Foundation
. Corgenix has selected three
subcontractors to assist on the project: Tulane University, Autoimmune
Technologies, LLC and Zalgen Labs, LLC.

“The scope and seriousness of Ebola virus outbreaks have resulted in an
increased urgency to bring testing and products to market as soon as
possible,” said Douglass Simpson, Corgenix president and CEO. “We thank
the Gates and Allen foundations for their support and commitment to our
efforts to accelerate the development of a rapid test.”

The Corgenix point-of-care test kit currently under development is
designed to be used in any clinical or field lab to determine in a
matter of minutes if a patient is infected with Ebola. Corgenix and the Viral
Hemorrhagic Fever Consortium
(VHFC), a collaboration of academic and
industry members headed by Tulane University and partially funded with
support from the NIH, have already developed the ReLASV®
rapid test
for the Lassa fever virus. The Lassa product is CE marked
as a diagnostic test, enabling its use as a diagnostic product in Europe
and other countries that recognize the European standard.

“Accurate, rapid, point-of-care testing will be critical to helping
contain future Ebola and Lassa virus outbreaks,” said Robert
Garry
, Ph.D., professor of Microbiology and Immunology at the Tulane
University School of Medicine
. “This grant will help ensure that our
consortium develops this diagnostic testing tool as quickly as possible.”

Current testing for the Ebola virus requires special biohazard handling
and sending test samples long distances to special labs – a process that
takes several days. This results in a critical loss of time to diagnose,
treat and help prevent the spread of the virus. Development of the
Corgenix Ebola test would enable rapid response to public health and
bioterrorism threats posed by the deadly virus.

The Corgenix Ebola products are not currently cleared or approved by any
regulatory authority for diagnostic use.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases (including
the world’s only non-blood-based test for aspirin effect), bone and
joint disorders and a line of unique detection products for viral
hemorrhagic disease. Corgenix diagnostic products are commercialized for
use in clinical laboratories throughout the world. The company currently
sells over 50 diagnostic products through a global distribution network
and has significant experience in product submissions to the FDA and
other worldwide regulatory authorities. Additionally, Corgenix contract
develops and manufactures products for key medical and life science
companies in state-of-the-art facilities in Colorado. The company
operates under a Quality Management System that is ISO 13485:2012
certified and compliant with FDA regulations. More information is
available at www.corgenix.com
(Corporate website) and www.corgenix.net
(Contract Services website).

Statements in this press release that are not strictly historical
facts are “forward-looking” statements (identified by the words
“believe”, “estimate”, “project”, “expect” or similar expressions)
within the meaning of the Private Securities Litigation Reform Act of
1995. These statements inherently involve risks and uncertainties that
could cause actual results to differ materially from the forward-looking
statements. Factors
that would cause or contribute to such
differences include, but are not limited to, continued acceptance of the
Company’s products and services in the marketplace, competitive factors,
changes in the regulatory environment, and other risks detailed in the
Company’s periodic report filings with the Securities and Exchange
Commission. The statements in this press release are made as of today,
based upon information currently known to management, and the Company
does not undertake any obligation to publicly update or revise any
forward-looking statements.

Copyright © 2014 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/CONX/news?id=94336

Leave a Reply

WP2Social Auto Publish Powered By : XYZScripts.com
Bunk Beds